|
| | | EXACERBATION | OCS sparing | QoL | SAFETY |
|
| MEPOLIZUMAB | Pavord et al. [7] | exacerbation (48%with 75mg dose/39% with 250mg dose/52% with 750mg dose) | not performed | no improvement of QoL (tests using AQLQ ) | common: headache, nasopharyngitis, infusion related reaction
Serious: 3 death (1 septic shock after acute pancreatitis, fatal asthma attack, suicide) |
| FloodPage et al. [8] | no significant difference between groups (16% placebo, 18 % 250 mg, 10% 750 mg) | not performed | improvement in treated patients, with all dose | serious: placebo (bladder carcinoma, unintended pregnancy, and asthma exacerbation); 250 mg of mepolizumab (hydrocephalus/cerebrovascular disorder, constipation, and gastrointestinal disturbance); 750 mg of mepolizumab (asthma exacerbation) |
| Bet et al. [9] | 32% exacerbation less | reducing daily dosage ( 2,65 times more than patient receiving placebo) | small change in ACQ | common: headache, nasopharyngitis, infusion related reaction
Serious: asthma exacerbation, pneumonia (both in placebo group) |
| Ortega et al. [10] | exacerbation (with intravenous medication, 47%; with subcutaneous administration, 53%) | not performed | improvement in QoL | common: headache, nasopharyngitis, upper respiratory tract infection |
| Nair et al. [11] | reduction of exacerbations in treated patients | reducing daily dosage | not performed | common: 1 patient with shortness of breath, 1 with aches and tiredness
serious: 1 death in placebo group |
| Chupp et al. [12] | reduction of exacerbations of 58% | not performed | improvement of QoL (tests using SGRQ) | common: headache, nasopharyngitis, urticaria, arthralgia, arrhythmias, injection-site reaction Serious: 8 arrhythmias (2 in mepolizumab and 6 in placebo), 1 deep venous thrombosis in mepolizumab group |
|
| RESLIZUMAB | Castro et al. [13] | exacerbation (people without exacerbation: 44%with placebo, 61% with reslizumab) | no improvement in OCS sparing | improvement of QoL (test using ACQ) | common: nasopharyngitis, upper respiratory tract infection
serious: 2 anaphylactic reaction |
| Castro et al. [14] | exacerbation (people without exacerbation:52% with placebo,73% with reslizumab) | no improvement in OCS sparing | improvement of QoL (test using AQLQ and ACQ-7) | common: nasopharyngitis
serious: pneumonia, worsening of asthma |
| Corren et al. [15] | not performed due to the short observation period (16 weeks) | not performed | improvement of QoL (test using ACQ-7) | serious: 2 anaphylactic reactions, 1 colon cancer (all in reslizumab group) |
| Bjemer et al. [16] | not performed due to the short observation period (16 weeks) | not performed | improvement of QoL (test using ACQ and AQLQ) | serious: placebo (1 acute myocardial infarction), 3 asthma exacerbations, 1 sinusitis, 1 pneumonia, 1 road traffic accident and 1 rib fracture |
|
| BENRALIZUMAB | Castro et al. [17] | no difference in noneosinophilic patients between benralizumab and placebo. Reduction in eosinophilic patients. | not performed | improvement in AQLQ in people with at least 300 eosinophils/mmc | serious: 100 mg dosage acute cholecystitis, herpes zoster, polyarteritis nodosa, and uterine leiomyoma 20 mg dosage: erythema nodosum |
| Nowak et al. [18] | exacerbation (49%) and exacerbation requiring hospitalization (60%) | not performed | no significant improve in ACQ and AQLQ | common: headache, asthma, dizziness, cough, pyrexia, bronchitis, anxiety, muscle spasm
serious: tachycardia and anxiety |
| Bleecker et al. [19] | exacerbation in Q4W and Q8W | not performed | improvement in patients with baseline | common: nasopharyngitis, worsening of asthma
serious: allergic granulomatous angiitis, panic attack, paraesthesia |
| Fitzgerald et al. [20] | exacerbation in Q4W and Q8W | not performed | blood eosinophils ≥300 cells per μL | common: nasopharyngitis, worsening of asthma
serious: urticaria, asthma, herpes zoster, chest pain |
| Nair et al. [21] | exacerbation (55% with 30 mg dose every 4 weeks; 70% with 30 mg dose every 8 weeks) | interruption of OCS (56% of who received drug every 4 weeks and 52% of 8 weeks administration, as compared with 19% treated with placebo) | improvement in patients with baseline | serious: worsening of asthma, pneumonia, hearth failure, pericarditis (placebo). Two case of death in Q8W due to pneumonia and acute cardiac failure. |
|
